EXEL Earnings

EXEL reported its earnings on 2026-02-10, showcasing a revenue of 598.66M against an estimate of 599.93M, resulting in a -0.21% surprise. The EPS was 0.94, surpassing the expected 0.84 by 11.9%. The stock experienced a -0.09% price change on the earnings day and a 2.56% change over the next five days, reflecting market reactions to the results.

Following EXEL's earnings announcement on 2026-02-10, the stock price moved by -0.09% on the day of the release. Over the subsequent five days, it saw a 2.56% change. Historically, EXEL's stock price tends to shift by an average of 0.09% in the 10 days leading up to earnings and 5.32% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate EXEL's annual revenue to reach 624.59M, while the EPS is projected at 0.75. These estimates reflect recent revisions, with revenue estimates revised downward by -0.04% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between EXEL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -0.04%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, EXEL's stock price typically moves by 0.09% in the 10 days before its earnings and 5.32% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.75 and revenue of 624.59M.

The earnings call summary indicates strong financial performance with tightened revenue guidance and lowered expense guidance. Product development is promising, with potential NDA filings and pivotal trials. The Q&A section reveals confidence in market strategy, particularly in colorectal cancer and RCC. Despite some uncertainties in 340B purchasing and pricing trends, the overall sentiment is positive, supported by a significant share repurchase plan. The absence of market cap data limits the precision of the prediction, but the positive financial and strategic outlook suggests a likely stock price increase.